Clinical Trials Logo

Clinical Trial Summary

This trial will study the efficacy and safety of a fixed dose of asenapine in participants diagnosed with Bipolar 1 Disorder. Participants who qualify for the study will be randomly assigned to receive a fixed dose of asenapine (either 5 mg or 10 mg twice daily [BID]) or placebo (BID) for 3 weeks. Throughout the trial, observations will be made on each participant at various times to assess the safety and effectiveness of the study treatment. The primary hypothesis is that there is at least one dose of asenapine that is superior to placebo in the change from baseline in manic symptoms (as measured by Young Mania Rating Scale [YMRS]) at Day 21 of the trial.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00764478
Study type Interventional
Source Organon and Co
Contact
Status Completed
Phase Phase 3
Start date April 6, 2012
Completion date May 28, 2014

See also
  Status Clinical Trial Phase
Recruiting NCT05400785 - Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning N/A
Withdrawn NCT01981811 - Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder Phase 2
Recruiting NCT04580134 - CLOZAPINE Response in Biotype-1 Phase 4
Terminated NCT03643159 - A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder Phase 4
Completed NCT02050854 - Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia N/A
Completed NCT01396291 - Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384) Phase 3
Completed NCT03386851 - Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
Terminated NCT01674010 - Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder Phase 2